International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationsRadiotherapeutic Management of Osseous Metastases: A Survey of Current Patterns of Care
Introduction
Osseous metastases represent the most common cause of intractable pain in cancer patients [1]. Bone metastases develop in up to 70% of newly diagnosed cancer patients [2]and result in immobility, anxiety, and depression, severely diminishing the patients’ quality of life. Despite a variety of treatment options, cancer pain remains inadequately managed for most patients 3, 4. This underscores the need for physicians treating cancer patients to become familiar with the management of this problem.
Pain secondary to osseous metastases can be managed with analgesics, cytotoxic chemotherapy, hormonal therapy, bisphosphonates, and radiotherapy. The goal of palliation is to provide expedient and durable relief of pain. Local-field external-beam irradiation (LF) has been the mainstay of treatment, as it is effective in 70% of patients [5]. The optimal dose and fractionation schemes have not yet been well defined, with most studies failing to demonstrate a dose–response effect 5, 6, 7.
Alternative radiotherapeutic approaches include the use of hemibody irradiation (HBI) and systemic radionuclide therapy (SR). Both of these types of therapy represent a more systemic approach, addressing more (or all) involved sites. HBI can produce complete and partial responses in 20% and 73% of cases, respectively [8]. However, it is an elaborate undertaking which may require hospitalization and has been associated with substantial morbidity. The Radiation Therapy Oncology Group (RTOG) reported severe and life-threatening gastrointestinal and hematological toxicity in 13% and 10% of patients, respectively, with the use of lower- and middle-half-body irradiation, and 16% and 32% of patients, respectively, with the use of upper-half-body irradiation [8]. In a later study limiting the HBI dose to 8 Gy, RTOG reported grade 3/4 gastrointestinal and hematological toxicity in 2% and 7% of patients, respectively [9].
Recently approved by the Food and Drug Administration, strontium-89 is a useful addition to available treatment options. Selective absorption into bone metastases limits irradiation of normal tissues and increases the therapeutic ratio. Administration as a single intravenous injection in the outpatient clinic is a further advantage for many patients. Other radionuclides, including samarium-153 and rhenium-186, are under clinical investigation.
With several effective options available, some just recently introduced, we sought to survey the current approaches of the radiotherapy community to the management of patients with bone metastases.
Section snippets
Methods and Materials
A total of 2500 questionnaires were sent to members of the American Society for Therapeutic Radiology and Oncology in the United States. A sample questionnaire is included in the Appendix A. Briefly, it consisted of 30 multiple-choice questions regarding four hypothetical clinical scenarios likely to be encountered in daily practice. Questions related to the radiotherapeutic technique of choice [local field vs. hemibody radiotherapy], the use of systemic radionuclides, fractionation schemes,
Results
A total of 817 physicians (33%) returned responses, for a total of 3268 cases. The distribution of the first year of practice and type of practice in the population of responders are shown in Fig. 1, Fig. 2, respectively. Data on the distribution of the type of practice were obtained from the research department of the American College of Radiology (ACR). These data were collected during the ACR 1995 survey. A comparison between the population and sample vectors of proportions using the
Discussion
The vast majority of patients with bone metastases can be managed successfully with LF external-beam radiotherapy [11]. Our results suggest that this is commonly believed by the radiation oncology community in the United States, where it is the most commonly used modality. LF was used, alone or in combination with other forms of therapy, in 54% and 74% of patients, respectively.
Despite a number of prospective clinical trials (Table 4), the optimal dose and fractionation have not yet been
References (23)
- et al.
A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain
Radiother. Oncol.
(1992) - et al.
Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases
Radiother. Oncol.
(1986) - et al.
A report of RTOG 8206A phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases
Int. J. Radiat. Oncol. Biol. Phys.
(1992) - et al.
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
Radiother. Oncol.
(1994) - et al.
Results of a randomized phase- III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
Int. J. Radiat. Oncol. Biol. Phys.
(1993) - et al.
A prospective randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
Eur. J. Cancer
(1991) Half body irradiation in the treatment of metastatic carcinomas
Clin. Radiol.
(1981)- et al.
Hemibody radiotherapy in the management of metastatic carcinoma
Clin. Radiol.
(1987) The treatment of cancer pain
N. Engl. J. Med.
(1985)- et al.
Treatment of metastatic cancer to bone
Pain and its treatment in outpatients with metastatic cancer
N. Engl. J. Med.
Cited by (96)
The Effect of Race in the Palliative Treatment of Bone Metastases
2022, Practical Radiation OncologyESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases
2022, Radiotherapy and OncologyMetastatic bone cancer: Consideration for optimal dose fractionation in radiation therapy
2022, Journal of Medical Imaging and Radiation SciencesCitation Excerpt :Conventional fractionation schemes for curative radiation prescriptions are typically 180-200 cGy per fraction given 5 days per week with varying total doses for different cancer types and treatment intents [1]. For palliative purposes, perhaps the most common dose in the United States has been 300 cGy per fraction, given for 10 fractions, to a total dose of 3000 cGy [6–9]. In Canada, the most common dose fractionation regimen for palliative bone metastasis has likely been 20 Gy given over five fractions [10–12].
National Quality Improvement Participation Among US Radiation Oncology Facilities: Compliance with Guideline-Concordant Palliative Radiation Therapy for Bone Metastases
2020, International Journal of Radiation Oncology Biology Physics